organization · Reporting owner

Bain Capital Life Sciences Fund IV, L.P.

Disclosed activity across 2 companies

Tapewire entity: 51906
SEC CIK: 0001996979

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Kailera Therapeutics, Inc.KLRA · Entity 4435	10% owner	April 20, 2026	April 20, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Kailera Therapeutics, Inc.

Report date April 20, 2026 · Filed April 20, 2026

Jointly reported with Bain Capital Life Sciences Investors, LLC, Bain Capital Life Sciences IV General Partner, LLC, BCLS Fund IV Investments GP, LLC, BCLS Fund IV Investments, L.P.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectSee footnotes	22,583,268	Last balance in matching sequence After 2026-04-20 transaction · row 3 Source-order balances reconcile. Account continuity and personal attribution are not independently verified. 3 source rows Row 1 · 2026-04-20 · Conversion · Acquired 16,875,000 · Balance 16,875,000 F1: Each share of the Issuer's Series A-1 Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 1:1 basis upon the closing of the Issuer's initial public offering. These securities had no expiration date. F3: Represents securities held directly by BCLS Fund IV Investments, LP ("BCLS Fund IV Investments"). F4: Bain Capital Life Sciences Investors, LLC ("BCLSI") is the manager of Bain Capital Life Sciences IV General Partner, LLC ("BCLS Fund IV GP"), which is the general partner of Bain Capital Life Sciences Fund IV, L.P. ("BCLS Fund IV"), which is the managing member of BCLS Fund IV Investments GP, LLC ("BCLS Fund IV Investments GP"), which is the general partner of BCLS Fund IV Investments. As a result, each of BCLSI, BCLS Fund IV GP, BCLS Fund IV and BCLS Fund IV Investments GP may be deemed to share voting and dispositive power with respect to the securities held by BCLS Fund IV Investments. BCLSI, BCLS Fund IV GP, BCLS Fund IV and BCLS Fund IV Investments GP each disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. Row 2 · 2026-04-20 · Conversion · Acquired 4,145,768 · Balance 21,020,768 F2: Each share of the Issuer's Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 1:1 basis upon the closing of the Issuer's initial public offering. These securities had no expiration date. F3: Represents securities held directly by BCLS Fund IV Investments, LP ("BCLS Fund IV Investments"). F4: Bain Capital Life Sciences Investors, LLC ("BCLSI") is the manager of Bain Capital Life Sciences IV General Partner, LLC ("BCLS Fund IV GP"), which is the general partner of Bain Capital Life Sciences Fund IV, L.P. ("BCLS Fund IV"), which is the managing member of BCLS Fund IV Investments GP, LLC ("BCLS Fund IV Investments GP"), which is the general partner of BCLS Fund IV Investments. As a result, each of BCLSI, BCLS Fund IV GP, BCLS Fund IV and BCLS Fund IV Investments GP may be deemed to share voting and dispositive power with respect to the securities held by BCLS Fund IV Investments. BCLSI, BCLS Fund IV GP, BCLS Fund IV and BCLS Fund IV Investments GP each disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. Row 3 · 2026-04-20 · Purchase · Acquired 1,562,500 · Balance 22,583,268 F3: Represents securities held directly by BCLS Fund IV Investments, LP ("BCLS Fund IV Investments"). F4: Bain Capital Life Sciences Investors, LLC ("BCLSI") is the manager of Bain Capital Life Sciences IV General Partner, LLC ("BCLS Fund IV GP"), which is the general partner of Bain Capital Life Sciences Fund IV, L.P. ("BCLS Fund IV"), which is the managing member of BCLS Fund IV Investments GP, LLC ("BCLS Fund IV Investments GP"), which is the general partner of BCLS Fund IV Investments. As a result, each of BCLSI, BCLS Fund IV GP, BCLS Fund IV and BCLS Fund IV Investments GP may be deemed to share voting and dispositive power with respect to the securities held by BCLS Fund IV Investments. BCLSI, BCLS Fund IV GP, BCLS Fund IV and BCLS Fund IV Investments GP each disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein.
Series A-1 Preferred StockSEC Table II · derivative / convertible security	IndirectSee footnotes	0	Reported balance After 2026-04-20 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2026-04-20 · Conversion · Disposed 16,875,000 · Balance 0 F1: Each share of the Issuer's Series A-1 Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 1:1 basis upon the closing of the Issuer's initial public offering. These securities had no expiration date. F3: Represents securities held directly by BCLS Fund IV Investments, LP ("BCLS Fund IV Investments"). F4: Bain Capital Life Sciences Investors, LLC ("BCLSI") is the manager of Bain Capital Life Sciences IV General Partner, LLC ("BCLS Fund IV GP"), which is the general partner of Bain Capital Life Sciences Fund IV, L.P. ("BCLS Fund IV"), which is the managing member of BCLS Fund IV Investments GP, LLC ("BCLS Fund IV Investments GP"), which is the general partner of BCLS Fund IV Investments. As a result, each of BCLSI, BCLS Fund IV GP, BCLS Fund IV and BCLS Fund IV Investments GP may be deemed to share voting and dispositive power with respect to the securities held by BCLS Fund IV Investments. BCLSI, BCLS Fund IV GP, BCLS Fund IV and BCLS Fund IV Investments GP each disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein.
Series B Preferred StockSEC Table II · derivative / convertible security	IndirectSee footnotes	0	Reported balance After 2026-04-20 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2026-04-20 · Conversion · Disposed 4,145,768 · Balance 0 F2: Each share of the Issuer's Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 1:1 basis upon the closing of the Issuer's initial public offering. These securities had no expiration date. F3: Represents securities held directly by BCLS Fund IV Investments, LP ("BCLS Fund IV Investments"). F4: Bain Capital Life Sciences Investors, LLC ("BCLSI") is the manager of Bain Capital Life Sciences IV General Partner, LLC ("BCLS Fund IV GP"), which is the general partner of Bain Capital Life Sciences Fund IV, L.P. ("BCLS Fund IV"), which is the managing member of BCLS Fund IV Investments GP, LLC ("BCLS Fund IV Investments GP"), which is the general partner of BCLS Fund IV Investments. As a result, each of BCLSI, BCLS Fund IV GP, BCLS Fund IV and BCLS Fund IV Investments GP may be deemed to share voting and dispositive power with respect to the securities held by BCLS Fund IV Investments. BCLSI, BCLS Fund IV GP, BCLS Fund IV and BCLS Fund IV Investments GP each disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein.

Filing footnotes · ownership attribution and instrument terms

F1: Each share of the Issuer's Series A-1 Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 1:1 basis upon the closing of the Issuer's initial public offering. These securities had no expiration date.

F2: Each share of the Issuer's Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 1:1 basis upon the closing of the Issuer's initial public offering. These securities had no expiration date.

F3: Represents securities held directly by BCLS Fund IV Investments, LP ("BCLS Fund IV Investments").

F4: Bain Capital Life Sciences Investors, LLC ("BCLSI") is the manager of Bain Capital Life Sciences IV General Partner, LLC ("BCLS Fund IV GP"), which is the general partner of Bain Capital Life Sciences Fund IV, L.P. ("BCLS Fund IV"), which is the managing member of BCLS Fund IV Investments GP, LLC ("BCLS Fund IV Investments GP"), which is the general partner of BCLS Fund IV Investments. As a result, each of BCLSI, BCLS Fund IV GP, BCLS Fund IV and BCLS Fund IV Investments GP may be deemed to share voting and dispositive power with respect to the securities held by BCLS Fund IV Investments. BCLSI, BCLS Fund IV GP, BCLS Fund IV and BCLS Fund IV Investments GP each disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Olema Pharmaceuticals, Inc.

Report date January 08, 2025 · Filed January 13, 2025

Jointly reported with Bain Capital Life Sciences Investors, LLC, Bain Capital Life Sciences IV General Partner, LLC, Bain Capital Life Sciences Opportunities IV GP, LLC, Bain Capital Life Sciences Opportunities IV, L.P.

Section 16 reporting ended · disclosed 2025-01-13. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectSee footnotes	4,300,000	Last balance in matching sequence After 2025-01-10 transaction · row 2 Source-order balances reconcile. Account continuity and personal attribution are not independently verified. 2 source rows Row 1 · 2025-01-08 · Purchase · Acquired 300,000 · Balance 7,800,000 F3: The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $5.44 to $5.92, inclusive. The reporting persons undertake to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein. F1: Represents securities held directly by Bain Capital Life Sciences Opportunities IV, L.P. ("BCLS Opportunities IV"). F2: Bain Capital Life Sciences Investors, LLC ("BCLSI") is the manager of Bain Capital Life Sciences IV General Partner, LLC ("BCLS Fund IV GP"), which is the general partner of Bain Capital Life Sciences Fund IV, L.P. ("BCLS Fund IV"), which is the sole member of Bain Capital Life Sciences Opportunities IV GP, LLC ("BCLS Opportunities IV GP" and, together with BCLSI, BCLS Fund IV GP, BCLS Fund IV, BCLS Opportunities IV GP and BCLS Opportunities IV, the "Bain Capital Life Sciences Entities"), which is the general partner of BCLS Opportunities IV. As a result, each of BCLSI, BCLS Fund IV GP, BCLS Fund IV and BCLS Opportunities IV GP may be deemed to share voting and dispositive power with respect to the securities held by BCLS Opportunities IV. BCLSI, BCLS Fund IV GP, BCLS Fund IV and BCLS Opportunities IV GP each disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. Row 2 · 2025-01-10 · Other · Disposed 3,500,000 · Balance 4,300,000 F4: On January 10, 2025, BCLS Opportunities IV entered into an exchange agreement with the Issuer pursuant to which BCLS Opportunities IV exchanged 3,500,000 shares of Common Stock for a pre-funded warrant to purchase 3,500,000 shares of common stock in reliance on the exemption from registration contained in Section 3(a)(9) of the Securities Act of 1933, as amended. The exchange transaction did not result in any change in the Bain Capital Life Sciences Entities pecuniary interest in the subject equity securities. F1: Represents securities held directly by Bain Capital Life Sciences Opportunities IV, L.P. ("BCLS Opportunities IV"). F2: Bain Capital Life Sciences Investors, LLC ("BCLSI") is the manager of Bain Capital Life Sciences IV General Partner, LLC ("BCLS Fund IV GP"), which is the general partner of Bain Capital Life Sciences Fund IV, L.P. ("BCLS Fund IV"), which is the sole member of Bain Capital Life Sciences Opportunities IV GP, LLC ("BCLS Opportunities IV GP" and, together with BCLSI, BCLS Fund IV GP, BCLS Fund IV, BCLS Opportunities IV GP and BCLS Opportunities IV, the "Bain Capital Life Sciences Entities"), which is the general partner of BCLS Opportunities IV. As a result, each of BCLSI, BCLS Fund IV GP, BCLS Fund IV and BCLS Opportunities IV GP may be deemed to share voting and dispositive power with respect to the securities held by BCLS Opportunities IV. BCLSI, BCLS Fund IV GP, BCLS Fund IV and BCLS Opportunities IV GP each disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein.
Pre-Funded Warrant (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.00	IndirectSee footnotes	3,500,000	Reported balance After 2025-01-10 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2025-01-10 · Other · Acquired 3,500,000 · Balance 3,500,000 F4: On January 10, 2025, BCLS Opportunities IV entered into an exchange agreement with the Issuer pursuant to which BCLS Opportunities IV exchanged 3,500,000 shares of Common Stock for a pre-funded warrant to purchase 3,500,000 shares of common stock in reliance on the exemption from registration contained in Section 3(a)(9) of the Securities Act of 1933, as amended. The exchange transaction did not result in any change in the Bain Capital Life Sciences Entities pecuniary interest in the subject equity securities. F5: BCLS Opportunities IV is prohibited from exercising this pre-funded warrant if the Bain Capital Life Sciences Entities would, in the aggregate, beneficially own more than 9.99% of the total number of shares of common stock then issued and outstanding immediately after giving effect to such exercise. F6: The pre-funded warrant does not expire. F1: Represents securities held directly by Bain Capital Life Sciences Opportunities IV, L.P. ("BCLS Opportunities IV"). F2: Bain Capital Life Sciences Investors, LLC ("BCLSI") is the manager of Bain Capital Life Sciences IV General Partner, LLC ("BCLS Fund IV GP"), which is the general partner of Bain Capital Life Sciences Fund IV, L.P. ("BCLS Fund IV"), which is the sole member of Bain Capital Life Sciences Opportunities IV GP, LLC ("BCLS Opportunities IV GP" and, together with BCLSI, BCLS Fund IV GP, BCLS Fund IV, BCLS Opportunities IV GP and BCLS Opportunities IV, the "Bain Capital Life Sciences Entities"), which is the general partner of BCLS Opportunities IV. As a result, each of BCLSI, BCLS Fund IV GP, BCLS Fund IV and BCLS Opportunities IV GP may be deemed to share voting and dispositive power with respect to the securities held by BCLS Opportunities IV. BCLSI, BCLS Fund IV GP, BCLS Fund IV and BCLS Opportunities IV GP each disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein.

Filing footnotes · ownership attribution and instrument terms

F1: Represents securities held directly by Bain Capital Life Sciences Opportunities IV, L.P. ("BCLS Opportunities IV").

F2: Bain Capital Life Sciences Investors, LLC ("BCLSI") is the manager of Bain Capital Life Sciences IV General Partner, LLC ("BCLS Fund IV GP"), which is the general partner of Bain Capital Life Sciences Fund IV, L.P. ("BCLS Fund IV"), which is the sole member of Bain Capital Life Sciences Opportunities IV GP, LLC ("BCLS Opportunities IV GP" and, together with BCLSI, BCLS Fund IV GP, BCLS Fund IV, BCLS Opportunities IV GP and BCLS Opportunities IV, the "Bain Capital Life Sciences Entities"), which is the general partner of BCLS Opportunities IV. As a result, each of BCLSI, BCLS Fund IV GP, BCLS Fund IV and BCLS Opportunities IV GP may be deemed to share voting and dispositive power with respect to the securities held by BCLS Opportunities IV. BCLSI, BCLS Fund IV GP, BCLS Fund IV and BCLS Opportunities IV GP each disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein.

F3: The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $5.44 to $5.92, inclusive. The reporting persons undertake to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein.

F4: On January 10, 2025, BCLS Opportunities IV entered into an exchange agreement with the Issuer pursuant to which BCLS Opportunities IV exchanged 3,500,000 shares of Common Stock for a pre-funded warrant to purchase 3,500,000 shares of common stock in reliance on the exemption from registration contained in Section 3(a)(9) of the Securities Act of 1933, as amended. The exchange transaction did not result in any change in the Bain Capital Life Sciences Entities pecuniary interest in the subject equity securities.

F5: BCLS Opportunities IV is prohibited from exercising this pre-funded warrant if the Bain Capital Life Sciences Entities would, in the aggregate, beneficially own more than 9.99% of the total number of shares of common stock then issued and outstanding immediately after giving effect to such exercise.

F6: The pre-funded warrant does not expire.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
April 20, 2026 Filed Apr 20, 2026 22:01 UTC	Kailera Therapeutics, Inc. KLRA · Entity 4435	ConversionSeries B Preferred Stock · Derivative	4,145,768	$0.00	$0.00	Disclosure SEC source: 0001193125-26-164389 · ownership.xml · derivative · entry 5 Bain Capital Life Sciences Investors, LLC · CIK 0001703031 · 10% owner Bain Capital Life Sciences IV General Partner, LLC · CIK 0001996931 · 10% owner Bain Capital Life Sciences Fund IV, L.P. · CIK 0001996979 · 10% owner BCLS Fund IV Investments GP, LLC · CIK 0002015967 · 10% owner BCLS Fund IV Investments, L.P. · CIK 0002015454 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 0 Underlying: Common Stock · 4,145,768 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each share of the Issuer's Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 1:1 basis upon the closing of the Issuer's initial public offering. These securities had no expiration date. F2 · derivative.exercise_date: Each share of the Issuer's Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 1:1 basis upon the closing of the Issuer's initial public offering. These securities had no expiration date. F2 · derivative.expiration_date: Each share of the Issuer's Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 1:1 basis upon the closing of the Issuer's initial public offering. These securities had no expiration date. F3 · ownership.nature: Represents securities held directly by BCLS Fund IV Investments, LP ("BCLS Fund IV Investments"). F4 · ownership.nature: Bain Capital Life Sciences Investors, LLC ("BCLSI") is the manager of Bain Capital Life Sciences IV General Partner, LLC ("BCLS Fund IV GP"), which is the general partner of Bain Capital Life Sciences Fund IV, L.P. ("BCLS Fund IV"), which is the managing member of BCLS Fund IV Investments GP, LLC ("BCLS Fund IV Investments GP"), which is the general partner of BCLS Fund IV Investments. As a result, each of BCLSI, BCLS Fund IV GP, BCLS Fund IV and BCLS Fund IV Investments GP may be deemed to share voting and dispositive power with respect to the securities held by BCLS Fund IV Investments. BCLSI, BCLS Fund IV GP, BCLS Fund IV and BCLS Fund IV Investments GP each disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. Read SEC document
April 20, 2026 Filed Apr 20, 2026 22:01 UTC	Kailera Therapeutics, Inc. KLRA · Entity 4435	ConversionSeries A-1 Preferred Stock · Derivative	16,875,000	$0.00	$0.00	Disclosure SEC source: 0001193125-26-164389 · ownership.xml · derivative · entry 4 Bain Capital Life Sciences Investors, LLC · CIK 0001703031 · 10% owner Bain Capital Life Sciences IV General Partner, LLC · CIK 0001996931 · 10% owner Bain Capital Life Sciences Fund IV, L.P. · CIK 0001996979 · 10% owner BCLS Fund IV Investments GP, LLC · CIK 0002015967 · 10% owner BCLS Fund IV Investments, L.P. · CIK 0002015454 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 0 Underlying: Common Stock · 16,875,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of the Issuer's Series A-1 Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 1:1 basis upon the closing of the Issuer's initial public offering. These securities had no expiration date. F1 · derivative.exercise_date: Each share of the Issuer's Series A-1 Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 1:1 basis upon the closing of the Issuer's initial public offering. These securities had no expiration date. F1 · derivative.expiration_date: Each share of the Issuer's Series A-1 Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 1:1 basis upon the closing of the Issuer's initial public offering. These securities had no expiration date. F3 · ownership.nature: Represents securities held directly by BCLS Fund IV Investments, LP ("BCLS Fund IV Investments"). F4 · ownership.nature: Bain Capital Life Sciences Investors, LLC ("BCLSI") is the manager of Bain Capital Life Sciences IV General Partner, LLC ("BCLS Fund IV GP"), which is the general partner of Bain Capital Life Sciences Fund IV, L.P. ("BCLS Fund IV"), which is the managing member of BCLS Fund IV Investments GP, LLC ("BCLS Fund IV Investments GP"), which is the general partner of BCLS Fund IV Investments. As a result, each of BCLSI, BCLS Fund IV GP, BCLS Fund IV and BCLS Fund IV Investments GP may be deemed to share voting and dispositive power with respect to the securities held by BCLS Fund IV Investments. BCLSI, BCLS Fund IV GP, BCLS Fund IV and BCLS Fund IV Investments GP each disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. Read SEC document
April 20, 2026 Filed Apr 20, 2026 22:01 UTC	Kailera Therapeutics, Inc. KLRA · Entity 4435	PurchaseCommon Stock	1,562,500	$16.00	$25,000,000.00	Disclosure SEC source: 0001193125-26-164389 · ownership.xml · nonDerivative · entry 3 Bain Capital Life Sciences Investors, LLC · CIK 0001703031 · 10% owner Bain Capital Life Sciences IV General Partner, LLC · CIK 0001996931 · 10% owner Bain Capital Life Sciences Fund IV, L.P. · CIK 0001996979 · 10% owner BCLS Fund IV Investments GP, LLC · CIK 0002015967 · 10% owner BCLS Fund IV Investments, L.P. · CIK 0002015454 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 22,583,268 F3 · ownership.nature: Represents securities held directly by BCLS Fund IV Investments, LP ("BCLS Fund IV Investments"). F4 · ownership.nature: Bain Capital Life Sciences Investors, LLC ("BCLSI") is the manager of Bain Capital Life Sciences IV General Partner, LLC ("BCLS Fund IV GP"), which is the general partner of Bain Capital Life Sciences Fund IV, L.P. ("BCLS Fund IV"), which is the managing member of BCLS Fund IV Investments GP, LLC ("BCLS Fund IV Investments GP"), which is the general partner of BCLS Fund IV Investments. As a result, each of BCLSI, BCLS Fund IV GP, BCLS Fund IV and BCLS Fund IV Investments GP may be deemed to share voting and dispositive power with respect to the securities held by BCLS Fund IV Investments. BCLSI, BCLS Fund IV GP, BCLS Fund IV and BCLS Fund IV Investments GP each disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. Read SEC document
April 20, 2026 Filed Apr 20, 2026 22:01 UTC	Kailera Therapeutics, Inc. KLRA · Entity 4435	ConversionCommon Stock	4,145,768	Not disclosed	Not disclosed	Disclosure SEC source: 0001193125-26-164389 · ownership.xml · nonDerivative · entry 2 Bain Capital Life Sciences Investors, LLC · CIK 0001703031 · 10% owner Bain Capital Life Sciences IV General Partner, LLC · CIK 0001996931 · 10% owner Bain Capital Life Sciences Fund IV, L.P. · CIK 0001996979 · 10% owner BCLS Fund IV Investments GP, LLC · CIK 0002015967 · 10% owner BCLS Fund IV Investments, L.P. · CIK 0002015454 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 21,020,768 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Each share of the Issuer's Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 1:1 basis upon the closing of the Issuer's initial public offering. These securities had no expiration date. F3 · ownership.nature: Represents securities held directly by BCLS Fund IV Investments, LP ("BCLS Fund IV Investments"). F4 · ownership.nature: Bain Capital Life Sciences Investors, LLC ("BCLSI") is the manager of Bain Capital Life Sciences IV General Partner, LLC ("BCLS Fund IV GP"), which is the general partner of Bain Capital Life Sciences Fund IV, L.P. ("BCLS Fund IV"), which is the managing member of BCLS Fund IV Investments GP, LLC ("BCLS Fund IV Investments GP"), which is the general partner of BCLS Fund IV Investments. As a result, each of BCLSI, BCLS Fund IV GP, BCLS Fund IV and BCLS Fund IV Investments GP may be deemed to share voting and dispositive power with respect to the securities held by BCLS Fund IV Investments. BCLSI, BCLS Fund IV GP, BCLS Fund IV and BCLS Fund IV Investments GP each disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. Read SEC document
April 20, 2026 Filed Apr 20, 2026 22:01 UTC	Kailera Therapeutics, Inc. KLRA · Entity 4435	ConversionCommon Stock	16,875,000	Not disclosed	Not disclosed	Disclosure SEC source: 0001193125-26-164389 · ownership.xml · nonDerivative · entry 1 Bain Capital Life Sciences Investors, LLC · CIK 0001703031 · 10% owner Bain Capital Life Sciences IV General Partner, LLC · CIK 0001996931 · 10% owner Bain Capital Life Sciences Fund IV, L.P. · CIK 0001996979 · 10% owner BCLS Fund IV Investments GP, LLC · CIK 0002015967 · 10% owner BCLS Fund IV Investments, L.P. · CIK 0002015454 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 16,875,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of the Issuer's Series A-1 Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 1:1 basis upon the closing of the Issuer's initial public offering. These securities had no expiration date. F3 · ownership.nature: Represents securities held directly by BCLS Fund IV Investments, LP ("BCLS Fund IV Investments"). F4 · ownership.nature: Bain Capital Life Sciences Investors, LLC ("BCLSI") is the manager of Bain Capital Life Sciences IV General Partner, LLC ("BCLS Fund IV GP"), which is the general partner of Bain Capital Life Sciences Fund IV, L.P. ("BCLS Fund IV"), which is the managing member of BCLS Fund IV Investments GP, LLC ("BCLS Fund IV Investments GP"), which is the general partner of BCLS Fund IV Investments. As a result, each of BCLSI, BCLS Fund IV GP, BCLS Fund IV and BCLS Fund IV Investments GP may be deemed to share voting and dispositive power with respect to the securities held by BCLS Fund IV Investments. BCLSI, BCLS Fund IV GP, BCLS Fund IV and BCLS Fund IV Investments GP each disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. Read SEC document
January 10, 2025 Filed Jan 13, 2025 21:34 UTC	Olema Pharmaceuticals, Inc. OLMA · Entity 613	OtherPre-Funded Warrant (right to buy) · Derivative	3,500,000	Not disclosed Strike: $0.00	Not disclosed	Disclosure SEC source: 0000950170-25-004870 · ownership.xml · derivative · entry 3 Bain Capital Life Sciences Investors, LLC · CIK 0001703031 · 10% owner Bain Capital Life Sciences IV General Partner, LLC · CIK 0001996931 · 10% owner Bain Capital Life Sciences Fund IV, L.P. · CIK 0001996979 · 10% owner Bain Capital Life Sciences Opportunities IV GP, LLC · CIK 0002015657 · 10% owner Bain Capital Life Sciences Opportunities IV, L.P. · CIK 0002015553 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 3,500,000 Underlying: Common Stock · 3,500,000 shares Expires not disclosed F4 · kind: On January 10, 2025, BCLS Opportunities IV entered into an exchange agreement with the Issuer pursuant to which BCLS Opportunities IV exchanged 3,500,000 shares of Common Stock for a pre-funded warrant to purchase 3,500,000 shares of common stock in reliance on the exemption from registration contained in Section 3(a)(9) of the Securities Act of 1933, as amended. The exchange transaction did not result in any change in the Bain Capital Life Sciences Entities pecuniary interest in the subject equity securities. F5 · shares: BCLS Opportunities IV is prohibited from exercising this pre-funded warrant if the Bain Capital Life Sciences Entities would, in the aggregate, beneficially own more than 9.99% of the total number of shares of common stock then issued and outstanding immediately after giving effect to such exercise. F4 · price: On January 10, 2025, BCLS Opportunities IV entered into an exchange agreement with the Issuer pursuant to which BCLS Opportunities IV exchanged 3,500,000 shares of Common Stock for a pre-funded warrant to purchase 3,500,000 shares of common stock in reliance on the exemption from registration contained in Section 3(a)(9) of the Securities Act of 1933, as amended. The exchange transaction did not result in any change in the Bain Capital Life Sciences Entities pecuniary interest in the subject equity securities. F6 · derivative.expiration_date: The pre-funded warrant does not expire. F5 · derivative.underlying_shares: BCLS Opportunities IV is prohibited from exercising this pre-funded warrant if the Bain Capital Life Sciences Entities would, in the aggregate, beneficially own more than 9.99% of the total number of shares of common stock then issued and outstanding immediately after giving effect to such exercise. F5 · balance_after: BCLS Opportunities IV is prohibited from exercising this pre-funded warrant if the Bain Capital Life Sciences Entities would, in the aggregate, beneficially own more than 9.99% of the total number of shares of common stock then issued and outstanding immediately after giving effect to such exercise. F1 · ownership.nature: Represents securities held directly by Bain Capital Life Sciences Opportunities IV, L.P. ("BCLS Opportunities IV"). F2 · ownership.nature: Bain Capital Life Sciences Investors, LLC ("BCLSI") is the manager of Bain Capital Life Sciences IV General Partner, LLC ("BCLS Fund IV GP"), which is the general partner of Bain Capital Life Sciences Fund IV, L.P. ("BCLS Fund IV"), which is the sole member of Bain Capital Life Sciences Opportunities IV GP, LLC ("BCLS Opportunities IV GP" and, together with BCLSI, BCLS Fund IV GP, BCLS Fund IV, BCLS Opportunities IV GP and BCLS Opportunities IV, the "Bain Capital Life Sciences Entities"), which is the general partner of BCLS Opportunities IV. As a result, each of BCLSI, BCLS Fund IV GP, BCLS Fund IV and BCLS Opportunities IV GP may be deemed to share voting and dispositive power with respect to the securities held by BCLS Opportunities IV. BCLSI, BCLS Fund IV GP, BCLS Fund IV and BCLS Opportunities IV GP each disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. Read SEC document
January 10, 2025 Filed Jan 13, 2025 21:34 UTC	Olema Pharmaceuticals, Inc. OLMA · Entity 613	OtherCommon Stock	3,500,000	Not disclosed	Not disclosed	Disclosure SEC source: 0000950170-25-004870 · ownership.xml · nonDerivative · entry 2 Bain Capital Life Sciences Investors, LLC · CIK 0001703031 · 10% owner Bain Capital Life Sciences IV General Partner, LLC · CIK 0001996931 · 10% owner Bain Capital Life Sciences Fund IV, L.P. · CIK 0001996979 · 10% owner Bain Capital Life Sciences Opportunities IV GP, LLC · CIK 0002015657 · 10% owner Bain Capital Life Sciences Opportunities IV, L.P. · CIK 0002015553 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 4,300,000 F4 · kind: On January 10, 2025, BCLS Opportunities IV entered into an exchange agreement with the Issuer pursuant to which BCLS Opportunities IV exchanged 3,500,000 shares of Common Stock for a pre-funded warrant to purchase 3,500,000 shares of common stock in reliance on the exemption from registration contained in Section 3(a)(9) of the Securities Act of 1933, as amended. The exchange transaction did not result in any change in the Bain Capital Life Sciences Entities pecuniary interest in the subject equity securities. F4 · price: On January 10, 2025, BCLS Opportunities IV entered into an exchange agreement with the Issuer pursuant to which BCLS Opportunities IV exchanged 3,500,000 shares of Common Stock for a pre-funded warrant to purchase 3,500,000 shares of common stock in reliance on the exemption from registration contained in Section 3(a)(9) of the Securities Act of 1933, as amended. The exchange transaction did not result in any change in the Bain Capital Life Sciences Entities pecuniary interest in the subject equity securities. F1 · ownership.nature: Represents securities held directly by Bain Capital Life Sciences Opportunities IV, L.P. ("BCLS Opportunities IV"). F2 · ownership.nature: Bain Capital Life Sciences Investors, LLC ("BCLSI") is the manager of Bain Capital Life Sciences IV General Partner, LLC ("BCLS Fund IV GP"), which is the general partner of Bain Capital Life Sciences Fund IV, L.P. ("BCLS Fund IV"), which is the sole member of Bain Capital Life Sciences Opportunities IV GP, LLC ("BCLS Opportunities IV GP" and, together with BCLSI, BCLS Fund IV GP, BCLS Fund IV, BCLS Opportunities IV GP and BCLS Opportunities IV, the "Bain Capital Life Sciences Entities"), which is the general partner of BCLS Opportunities IV. As a result, each of BCLSI, BCLS Fund IV GP, BCLS Fund IV and BCLS Opportunities IV GP may be deemed to share voting and dispositive power with respect to the securities held by BCLS Opportunities IV. BCLSI, BCLS Fund IV GP, BCLS Fund IV and BCLS Opportunities IV GP each disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. Read SEC document
January 08, 2025 Filed Jan 13, 2025 21:34 UTC	Olema Pharmaceuticals, Inc. OLMA · Entity 613	PurchaseCommon Stock	300,000	$5.76	$1,727,370.00	Disclosure SEC source: 0000950170-25-004870 · ownership.xml · nonDerivative · entry 1 Bain Capital Life Sciences Investors, LLC · CIK 0001703031 · 10% owner Bain Capital Life Sciences IV General Partner, LLC · CIK 0001996931 · 10% owner Bain Capital Life Sciences Fund IV, L.P. · CIK 0001996979 · 10% owner Bain Capital Life Sciences Opportunities IV GP, LLC · CIK 0002015657 · 10% owner Bain Capital Life Sciences Opportunities IV, L.P. · CIK 0002015553 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 7,800,000 F3 · price: The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $5.44 to $5.92, inclusive. The reporting persons undertake to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein. F1 · ownership.nature: Represents securities held directly by Bain Capital Life Sciences Opportunities IV, L.P. ("BCLS Opportunities IV"). F2 · ownership.nature: Bain Capital Life Sciences Investors, LLC ("BCLSI") is the manager of Bain Capital Life Sciences IV General Partner, LLC ("BCLS Fund IV GP"), which is the general partner of Bain Capital Life Sciences Fund IV, L.P. ("BCLS Fund IV"), which is the sole member of Bain Capital Life Sciences Opportunities IV GP, LLC ("BCLS Opportunities IV GP" and, together with BCLSI, BCLS Fund IV GP, BCLS Fund IV, BCLS Opportunities IV GP and BCLS Opportunities IV, the "Bain Capital Life Sciences Entities"), which is the general partner of BCLS Opportunities IV. As a result, each of BCLSI, BCLS Fund IV GP, BCLS Fund IV and BCLS Opportunities IV GP may be deemed to share voting and dispositive power with respect to the securities held by BCLS Opportunities IV. BCLSI, BCLS Fund IV GP, BCLS Fund IV and BCLS Opportunities IV GP each disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.